Development of Basal Cell Carcinoma With Squamous Differentiation During Vismodegib Treatment

    loading  Checking for direct PDF access through Ovid


Vismodegib, a Smoothened (SMO) inhibitor, is a systemic treatment option for locally advanced and metastatic basal cell carcinoma (BCC) that functions by downregulating the Sonic Hedgehog (SHH) pathway responsible for BCC proliferation. With increased use of vismodegib since FDA-approval in 2012, reports of BCC recurrence, resistance, and development of secondary tumors, such as squamous cell carcinoma (SCC), are of rising clinical concern.

Related Topics

    loading  Loading Related Articles